Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

Identification of partial loss-of-function (hypomorphic), reduced penetrance pathogenic missense variants (RPPVs) and assessment of the clinical relevance of these variants is needed for improved hereditary cancer risk estimation. Here we show that 70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival, decrease RAD51 foci formation, and increase sensitivity to Poly(ADP-ribose) polymerase inhibitors. The 34 "strong" hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants (PVs), and 14 of these variants can be classified as "likely pathogenic" by integration of functional data into a ClinGen BRCA1/2 variant curation model. In addition, 32% of tumors with hypomorphic variants and corresponding loss of heterozygosity for BRCA2 display homologous recombination deficiency (HRD) compared to 83% of tumors with PVs and 7% with benign variants. These RPPVs represent a class of BRCA2 variants that have implications for the clinical management of carriers.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-17
DOI
https://doi.org/10.1038/s41467-026-79433-5
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

Chunling Hu, Rohan David Gnanaolivu, Lisa N. Heppler, Rachid Karam et al.
2 links
Nature Communications
BRCA gene mutations in cancer
article

Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

Chunling Hu, Rohan David Gnanaolivu, Lisa N. Heppler, Rachid Karam, Paulo Cilas Morais Lyra Junior, Matthew T. Kucera, Brennan James Decker, Fergus J. Couch, Colin C. Young, Amik Munankarmy, Ronan E. Couch, Kelly Fulk, Marcy E. Richardson, Tina F. Pesaran, Tuya Pal, Timothy C. Simmons, Yen Y. Tan, Benjamin P. Persons, Jamie D. Weyandt, Erin Mundt, Elisha Hughes, Scott H. Kaufmann, Huaizhi Huang, Wenan Chen, Susan M. Domchek, Álvaro N.A. Monteiro, Christen M. Csuy, Katherine L. Nathanson, Siddhartha Yadav, Nicholas James Boddicker, Steven N. Hart, Jie Na, Kevin L. Peterson, Christina A. Seelaus, Olivia K. Rossman, Mohamed Abozaid, Andrew Goldfarb, Zahra Heidari
article en

Abstract

Identification of partial loss-of-function (hypomorphic), reduced penetrance pathogenic missense variants (RPPVs) and assessment of the clinical relevance of these variants is needed for improved hereditary cancer risk estimation. Here we show that 70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival, decrease RAD51 foci formation, and increase sensitivity to Poly(ADP-ribose) polymerase inhibitors. The 34 "strong" hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants (PVs), and 14 of these variants can be classified as "likely pathogenic" by integration of functional data into a ClinGen BRCA1/2 variant curation model. In addition, 32% of tumors with hypomorphic variants and corresponding loss of heterozygosity for BRCA2 display homologous recombination deficiency (HRD) compared to 83% of tumors with PVs and 7% with benign variants. These RPPVs represent a class of BRCA2 variants that have implications for the clinical management of carriers.

Nature CommunicationsVol. 17(1)
Mayo Clinic (US), Moffitt Cancer Center (US), Ambry Genetics (United States) (US), Myriad Genetics (US), Vanderbilt-Ingram Cancer Center (US), Foundation Medicine (United States) (US), Medical University of Vienna (AT), University of Pennsylvania (US), Vanderbilt University Medical Center (US)
Breast Cancer Research Foundation, National Institutes of Health, National Cancer Institute
Good health and well-being
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon